WIRB-Copernicus Group announced that ePharmaSolutions has joined its group of companies.
WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services for clinical research, announced that ePharmaSolutions (ePS) has joined its group of companies. Based near Philadelphia, PA, ePS is a provider of eClinical solutions and technology-enabled services that improve the conduct of clinical trials. Its proprietary solutions, including a cloud-based enterprise Clinical Trial Portal (CTP) and Electronic Trial Master File (eTMF), are used by 350,000 clinical research professionals in 130 countries. WCG noted that the addition of ePS expands WCG’s eClinical offerings for improving clinical trial start-up and management.
Like the other companies within WCG, ePS will continue to operate independently and retain both its leadership and brand. WCG will support ePharmaSolutions as it continues to expand its platform solution with access to capital, complementary clinical expertise, corporate support, and integration of its technologies within the WCG family of companies.
Read the full release here.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.